177 related articles for article (PubMed ID: 11815384)
1. Cardioselectivity of the sulphonylurea HMR 1098: studies on native and recombinant cardiac and pancreatic K(ATP) channels.
Manning Fox JE; Kanji HD; French RJ; Light PE
Br J Pharmacol; 2002 Jan; 135(2):480-8. PubMed ID: 11815384
[TBL] [Abstract][Full Text] [Related]
2. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels.
Song DK; Ashcroft FM
Br J Pharmacol; 2001 May; 133(1):193-9. PubMed ID: 11325810
[TBL] [Abstract][Full Text] [Related]
3. HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels.
Zhang HX; Akrouh A; Kurata HT; Remedi MS; Lawton JS; Nichols CG
J Mol Cell Cardiol; 2011 Mar; 50(3):552-60. PubMed ID: 21185839
[TBL] [Abstract][Full Text] [Related]
4. Reduced effectiveness of HMR 1098 in blocking cardiac sarcolemmal K(ATP) channels during metabolic stress.
Rainbow RD; Norman RI; Hudman D; Davies NW; Standen NB
J Mol Cell Cardiol; 2005 Oct; 39(4):637-46. PubMed ID: 16099467
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides.
Reimann F; Dabrowski M; Jones P; Gribble FM; Ashcroft FM
J Physiol; 2003 Feb; 547(Pt 1):159-68. PubMed ID: 12562963
[TBL] [Abstract][Full Text] [Related]
6. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels.
Gribble FM; Tucker SJ; Seino S; Ashcroft FM
Diabetes; 1998 Sep; 47(9):1412-8. PubMed ID: 9726229
[TBL] [Abstract][Full Text] [Related]
7. Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels.
Lawrence CL; Rainbow RD; Davies NW; Standen NB
Br J Pharmacol; 2002 Jul; 136(5):746-52. PubMed ID: 12086984
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels.
Liu Y; Ren G; O'Rourke B; Marbán E; Seharaseyon J
Mol Pharmacol; 2001 Feb; 59(2):225-30. PubMed ID: 11160857
[TBL] [Abstract][Full Text] [Related]
9. Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A.
Cui Y; Tinker A; Clapp LH
Br J Pharmacol; 2003 May; 139(1):122-8. PubMed ID: 12746230
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
Chachin M; Yamada M; Fujita A; Matsuoka T; Matsushita K; Kurachi Y
J Pharmacol Exp Ther; 2003 Mar; 304(3):1025-32. PubMed ID: 12604678
[TBL] [Abstract][Full Text] [Related]
11. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel.
Reimann F; Proks P; Ashcroft FM
Br J Pharmacol; 2001 Apr; 132(7):1542-8. PubMed ID: 11264248
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide.
Russ U; Lange U; Löffler-Walz C; Hambrock A; Quast U
J Pharmacol Exp Ther; 2001 Dec; 299(3):1049-55. PubMed ID: 11714894
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxide revealed by ADP.
D'hahan N; Moreau C; Prost AL; Jacquet H; Alekseev AE; Terzic A; Vivaudou M
Proc Natl Acad Sci U S A; 1999 Oct; 96(21):12162-7. PubMed ID: 10518593
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of Kir6.2-SUR1 currents, in the absence and presence of sodium azide, to the K(ATP) channel inhibitors, ciclazindol and englitazone.
McKay NG; Kinsella JM; Campbell CM; Ashford ML
Br J Pharmacol; 2000 Jun; 130(4):857-66. PubMed ID: 10864893
[TBL] [Abstract][Full Text] [Related]
15. Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.
Felsch H; Lange U; Hambrock A; Löffler-Walz C; Russ U; Carroll WA; Gopalakrishnan M; Quast U
Br J Pharmacol; 2004 Apr; 141(7):1098-105. PubMed ID: 15023854
[TBL] [Abstract][Full Text] [Related]
16. Blockers of the ATP-sensitive potassium channel SUR2A/Kir6.2: a new approach to prevent sudden cardiac death.
Englert HC; Heitsch H; Gerlach U; Knieps S
Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):253-71. PubMed ID: 15326916
[TBL] [Abstract][Full Text] [Related]
17. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
[TBL] [Abstract][Full Text] [Related]
18. Functional effects of naturally occurring KCNJ11 mutations causing neonatal diabetes on cloned cardiac KATP channels.
Tammaro P; Proks P; Ashcroft FM
J Physiol; 2006 Feb; 571(Pt 1):3-14. PubMed ID: 16339180
[TBL] [Abstract][Full Text] [Related]
19. SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil.
Shindo T; Yamada M; Isomoto S; Horio Y; Kurachi Y
Br J Pharmacol; 1998 Jul; 124(5):985-91. PubMed ID: 9692785
[TBL] [Abstract][Full Text] [Related]
20. The mutation Y1206S increases the affinity of the sulphonylurea receptor SUR2A for glibenclamide and enhances the effects of coexpression with Kir6.2.
Stephan D; Stauss E; Lange U; Felsch H; Löffler-Walz C; Hambrock A; Russ U; Quast U
Br J Pharmacol; 2005 Apr; 144(8):1078-88. PubMed ID: 15711591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
